Cigna Files 8-K on Executive Compensatory Arrangements

TL;DR

**Cigna just filed an 8-K about executive pay changes, watch for leadership shifts.**

AI Summary

The Cigna Group filed an 8-K on January 17, 2024, reporting an event that occurred on January 16, 2024, related to changes in its executive compensation arrangements. This filing, under Item 5.02, indicates potential shifts in how certain officers are compensated, which could impact the company's financial performance and executive retention. Investors should note that changes in compensatory arrangements can signal strategic shifts or efforts to align executive incentives with shareholder value.

Why It Matters

Changes in executive compensation can influence leadership stability and motivation, directly affecting the company's strategic direction and long-term financial health.

Risk Assessment

Risk Level: low — This filing is purely administrative, reporting a change in compensatory arrangements, and does not inherently indicate a negative or positive event without further details.

Analyst Insight

Investors should monitor subsequent filings or company announcements for specific details regarding the changes in compensatory arrangements to understand their potential impact on executive incentives and company strategy.

Key Players & Entities

• The Cigna Group (company) — registrant filing the 8-K
• January 16, 2024 (date) — date of the earliest event reported
• January 17, 2024 (date) — filing date of the 8-K
• 001-38769 (other) — Commission File Number
• 82-4991898 (other) — IRS Employer Identification No.
• Delaware (other) — State of incorporation
• 900 Cottage Grove Road Bloomfield, Connecticut 06002 (other) — Address of principal executive offices
• 860-226-6000 (other) — Registrant's telephone number
• CI (other) — Trading Symbol for Common Stock
• New York Stock Exchange (other) — Exchange where Common Stock is registered

FAQ

From the Filing

0000950159-24-000014.txt : 20240117 0000950159-24-000014.hdr.sgml : 20240117 20240117092121 ACCESSION NUMBER: 0000950159-24-000014 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20240116 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20240117 DATE AS OF CHANGE: 20240117 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cigna Group CENTRAL INDEX KEY: 0001739940 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] ORGANIZATION NAME: 02 Finance IRS NUMBER: 824991898 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38769 FILM NUMBER: 24536916 BUSINESS ADDRESS: STREET 1: 900 COTTAGE GROVE ROAD CITY: BLOOMFIELD STATE: CT ZIP: 06002 BUSINESS PHONE: 8602266000 MAIL ADDRESS: STREET 1: 900 COTTAGE GROVE ROAD CITY: BLOOMFIELD STATE: CT ZIP: 06002 FORMER COMPANY: FORMER CONFORMED NAME: Cigna Corp DATE OF NAME CHANGE: 20181221 FORMER COMPANY: FORMER CONFORMED NAME: Halfmoon Parent, Inc. DATE OF NAME CHANGE: 20180508 8-K 1 cigna8k.htm THE CIGNA GROUP FORM 8-K false 0001739940 0001739940 2024-01-16 2024-01-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES   SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549   FORM  8-K     CURRENT REPORT   Pursuant to Section 13 or 15(d) of the   Securities Exchange Act of 1934   Date of Report (Date of earliest event reported) January 16, 2024   The Cigna Group   (Exact name of registrant as specified in its charter)   Delaware (State or other jurisdiction of incorporation) 001-38769 (Commission File Number) 82-4991898 (IRS Employer Identification No.)   900 Cottage Grove Road Bloomfield , Connecticut 06002   (Address of principal executive offices) (Zip Code)   Registrant’s telephone number, including area code:   ( 860 ) 226-6000   Not Applicable   (Former name or former address, if changed since last report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, Par Value $0.01 CI New York Stock Exchange , Inc.   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).   Emerging growth company  ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐           Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.   On January 17, 2024, The Cigna Group (the “Company”) announced certain organizational changes. Among these changes, effective February 5, 2024:   · Brian C. Evanko will serve as President and Chief Executive Officer, Cigna Heal